4.5 Article

A Randomized Trial of Comparing a Combination of Montelukast and Budesonide With Budesonide in Allergic Rhinitis

期刊

LARYNGOSCOPE
卷 131, 期 4, 页码 E1054-E1061

出版社

WILEY
DOI: 10.1002/lary.28433

关键词

Budesonide; montelukast; combination therapy; monotherapy; seasonal allergic rhinitis

资金

  1. National Key R&D Program of China [2018YFC0116801, 2016YFC0905200]
  2. National Natural Science Foundation of China [81570895, 81420108009, 81400444, 81870698, 81630023]
  3. Changjiang Scholars and Innovative Research Team [IRT13082]
  4. Special Fund of Capital Health Development [2011-1017-06, 2011-1017-02]
  5. Special Fund of Sanitation Elite Reconstruction of Beijing [2009-2-007]
  6. Beijing Municipal Administration of Hospitals' Mission Plan [SML20150203]
  7. Beijing Municipal Administration of Hospitals' Yangfan Plan [XMLX201816]
  8. Capital Citizenry Health Program [z161100000116062]

向作者/读者索取更多资源

The combination of budesonide and montelukast may have superior efficacy in treating seasonal allergic rhinitis compared to budesonide monotherapy, especially in improving nasal blockage and itching. Nasal cavity volume and nasal airway resistance can be used to assess nasal blockage more accurately.
Objectives/Hypothesis It is not unequivocally proven whether a combination of an intranasal corticosteroids (INSs) and a cysteinyl leukotriene receptor antagonist has greater efficacy than INSs in the treatment of seasonal allergic rhinitis (SAR). Study Design Single-center, randomized, open-label study. Methods Study subjects included 46 participants with SAR. Participants were randomized to receive budesonide (BD; 256 mu g) plus montelukast (MNT; 10 mg) (BD + MNT) or BD alone (256 mu g) for 2 weeks. Visual analog scale scores for five major symptoms of SAR, nasal cavity volume (NCV), nasal airway resistance (NAR), and fractional exhaled nitric oxide (FeNO) were assessed before and at the end of treatments. Results Both treatments significantly improved the five main SAR symptoms from baseline; however, BD + MNT produced significantly greater improvements in nasal blockage and nasal itching compared to BD alone. At baseline, the nasal blockage score was significantly correlated with NCV and NAR (r = -0.473, P = .002 and r = -0.383, P = .013, respectively). After 2 weeks of treatment, BD + MNT significantly improved NCV, but not NAR, to a greater level than BD. The number of patients with FeNO concentration >= 30 ppb at baseline was significantly decreased after BD + MNT treatment, but not after BD treatment. Similarly, BD + MNT treatment led to a significantly greater decrease in FeNO concentration than BD treatment. Conclusions BD + MNT treatment may have an overall superior efficacy than BD monotherapy for patients with SAR, especially in improvement of nasal blockage, itching, and subclinical lower airway inflammation. Also, NCV and NAR could be used to assess nasal blockage more accurately. Level of Evidence 1b Laryngoscope, 2019

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据